Compare WS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | GHRS |
|---|---|---|
| Founded | 1955 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2023 | 2021 |
| Metric | WS | GHRS |
|---|---|---|
| Price | $37.76 | $29.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $42.50 | $41.38 |
| AVG Volume (30 Days) | 200.4K | ★ 304.9K |
| Earning Date | 03-25-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $3,443,800,000.00 | N/A |
| Revenue This Year | $16.77 | N/A |
| Revenue Next Year | $2.69 | N/A |
| P/E Ratio | $224.59 | ★ N/A |
| Revenue Growth | ★ 11.33 | N/A |
| 52 Week Low | $27.22 | $11.83 |
| 52 Week High | $49.17 | $31.44 |
| Indicator | WS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 62.73 |
| Support Level | $38.01 | $12.83 |
| Resistance Level | $39.02 | $31.00 |
| Average True Range (ATR) | 1.79 | 1.39 |
| MACD | 0.36 | 0.04 |
| Stochastic Oscillator | 79.72 | 72.08 |
Worthington Steel Inc is a processor of carbon flat-rolled steel, a producer of laser-welded solutions, and a provider of electrical steel laminations. The company has manufacturing facilities across the United States, Canada, China, India, Germany and Mexico. It buys coils of steel from primary steel producers and processes them to precise type, thickness, length, width, shape, and surface quality required by customer specifications. The company's product lines and processing capabilities include; carbon flat-rolled steel processing, electrical steel laminations, and tailor welded products. Geographically, the company generates a majority of its revenue from the United States followed by Canada, Mexico, and other regions.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.